ALC on NYSE

Alcon

Logo: Alcon AG, Public domain, via Wikimedia Commons⁶

Swiss-American pharmaceutical and medical device company

Alcon Inc. (German: Alcon AG) is a Swiss-American pharmaceutical and medical device company specializing in eye care products. Alcon is incorporated in the Canton of Fribourg, Switzerland, and its global headquarters are located in Geneva, but its main operational base is in Fort Worth, Texas, United States, where it employs about 4,500 people. Alcon was a subsidiary of Novartis until April 2019, when it was spun out into a separate publicly traded company.³ Wikipedia text CC BY-SA 4.0

$66.15 down 0.43 (0.65%)Price as of Oct 16, 2026 at 19:58 UTC

Last updated Oct 21, 2026.

Overview

$10.4BRevenue, fiscal 2025⁷

$980.0MNet income, fiscal 2025⁷

1945Founded¹

Compare with Bausch & Lomb, The Cooper Companies or National Vision Holdings, Inc., or pick any stock.

TickerALC on NYSE¹
Industrypharmaceutical industry¹
HeadquartersGeneva¹
Founded inFort Worth¹
Websitewww.alcon.com
Legal formAktiengesellschaft¹
Listed onNew York Stock Exchange (ALC), Swiss Stock Exchange (ALC)¹
Incorporated inSwitzerland⁸
Business address6201 South Freeway, Fort Worth, Tx 76134⁸
Filer categoryLarge accelerated filer⁸
LEI549300LDT5AP8S0NBM78⁴
StatusActive⁴
LEI statusIssued and current⁴
Registered addressRUE LOUIS-D'AFFRY 6, 1701 Fribourg, Switzerland⁴
Registered withMinistry of Justice, CHE-234.781.164⁴

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

55.2%Gross margin⁷

13.1%Operating margin⁷

9.4%Net margin⁷

4.9%Revenue growth, 2025⁷

4.4%Return on equity⁷

0.19×Debt to equity⁷

$1.7BFree cash flow⁷

Where the money goes

Where each dollar of revenue went, fiscal 2025

Cost of revenueSelling, general and admin

Cost of revenue44¢$4.6B
Research and development10¢$990.0M
Selling, general and admin33¢$3.4B
Interest2¢$204.0M
Income tax2¢$180.0M
Profit9¢$980.0M

Out of $10.4B in revenue.⁷

Where each dollar of operating cash went, fiscal 2025

Capital spendingShare buybacksKept or used elsewhere

Capital spending24¢$543.0M
Dividends paid7¢$166.0M
Share buybacks30¢$676.0M
Kept or used elsewhere39¢$886.0M

Out of $2.3B of cash from operations.⁷

Financial statements

Revenue¹¹¹²¹³¹⁴¹⁵⁷$10.4B in 2025+45% since 2018

Gross profit¹¹¹²¹³¹⁴¹⁵⁷$5.7B in 2025+80% since 2018

Operating income¹¹¹²¹³¹⁴¹⁵⁷$1.4B in 2025

Net income¹¹¹²¹³¹⁴¹⁵⁷$980.0M in 2025

Every line of the income statement as filed: the last 3 fiscal years, latest first.⁷

Period ending	2025-12-31	2024-12-31	2023-12-31
Net sales	$10.3B	$9.8B	$9.4B
Other revenues	$82.0M	$75.0M	$85.0M
Net sales and other revenues	$10.4B	$9.9B	$9.5B
Cost of net sales	-$4.6B	-$4.3B	-$4.1B
Cost of other revenues	-$64.0M	-$71.0M	-$67.0M
Gross profit	$5.7B	$5.5B	$5.2B
Selling, general & administration	-$3.4B	-$3.2B	-$3.2B
Research & development	-$990.0M	-$876.0M	-$828.0M
Other income	$169.0M	$77.0M	$80.0M
Other expense	-$115.0M	-$50.0M	-$251.0M
Operating income	$1.4B	$1.4B	$1.0B
Interest expense	-$204.0M	-$192.0M	-$189.0M
Other financial income & expense	$22.0M	$43.0M	-$18.0M
Share of (loss) from associated companies	-$18.0M	-$8.0M	$0
Income before taxes	$1.2B	$1.3B	$832.0M
Taxes	-$180.0M	-$238.0M	$142.0M
Net income	$980.0M	$1.0B	$974.0M
Shareholders of Alcon Inc.	$980.0M	$1.0B	$974.0M
Non-controlling interests	$0	$0	$0
Basic (in dollars per share)	$1.99	$2.06	$1.98
Diluted (in dollars per share)	$1.98	$2.05	$1.96
Basic (in shares)	493.2M shares	494.4M shares	493.0M shares
Diluted (in shares)	496.2M shares	497.5M shares	496.5M shares

Total assets¹⁶¹¹¹²¹³¹⁴¹⁵⁷$31.6B in 2025+17% since 2018

Total liabilities¹⁶¹¹¹²¹³¹⁴¹⁵⁷$9.5B in 2025+115% since 2018

Shareholders’ equity¹²¹³¹⁴¹⁵⁷$22.0B in 2025−3% since 2018

Cash¹²¹³¹⁴¹⁵⁷$1.5B in 2025+573% since 2018

Long-term debt¹³¹⁴¹⁵⁷$4.2B in 2025+5% since 2021

Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.⁷

Period ending	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Property, plant & equipment	$4.8B	$4.4B
Right-of-use assets	$447.0M	$449.0M
Goodwill	$9.3B	$8.9B
Intangible assets other than goodwill	$9.0B	$8.6B
Deferred tax assets	$458.0M	$421.0M
Financial assets	$768.0M	$652.0M
Other non-current assets	$397.0M	$594.0M
Total non-current assets	$25.1B	$24.0B
Inventories	$2.4B	$2.3B
Trade receivables	$1.9B	$1.7B
Income tax receivables	$20.0M	$23.0M
Cash and cash equivalents	$1.5B	$1.7B	$1.1B	$980.0M
Time deposits	$80.0M	$153.0M
Other current assets	$489.0M	$453.0M
Total current assets	$6.4B	$6.3B
Total assets	$31.6B	$30.3B
Share capital	$20.0M	$20.0M
Reserves	$22.0B	$21.5B
Equity attributable to shareholders of Alcon Inc.	$22.0B	$21.6B
Non-controlling interests	$1.0M	$0
Total equity	$22.0B	$21.6B	$20.6B	$19.7B
Financial debts	$4.2B	$4.5B
Lease liabilities	$429.0M	$429.0M
Deferred tax liabilities	$941.0M	$724.0M
Provisions & other non-current liabilities	$939.0M	$825.0M
Total non-current liabilities	$6.5B	$6.5B
Trade payables	$926.0M	$773.0M
Financial debts	$575.0M	$105.0M
Lease liabilities	$80.0M	$68.0M
Current income tax liabilities	$182.0M	$104.0M
Provisions & other current liabilities	$1.3B	$1.2B
Total current liabilities	$3.0B	$2.3B
Total liabilities	$9.5B	$8.8B
Total equity and liabilities	$31.6B	$30.3B

Period ending	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Property, plant & equipment	$4.8B	$4.4B
Right-of-use assets	$447.0M	$449.0M
Goodwill	$9.3B	$8.9B
Intangible assets other than goodwill	$9.0B	$8.6B
Deferred tax assets	$458.0M	$421.0M
Financial assets	$768.0M	$652.0M
Other non-current assets	$397.0M	$594.0M
Total non-current assets	$25.1B	$24.0B
Inventories	$2.4B	$2.3B
Trade receivables	$1.9B	$1.7B
Income tax receivables	$20.0M	$23.0M
Cash and cash equivalents	$1.5B	$1.7B	$1.1B	$980.0M
Time deposits	$80.0M	$153.0M
Other current assets	$489.0M	$453.0M
Total current assets	$6.4B	$6.3B
Total assets	$31.6B	$30.3B
Share capital	$20.0M	$20.0M
Reserves	$22.0B	$21.5B
Equity attributable to shareholders of Alcon Inc.	$22.0B	$21.6B
Non-controlling interests	$1.0M	$0
Total equity	$22.0B	$21.6B	$20.6B	$19.7B
Financial debts	$4.2B	$4.5B
Lease liabilities	$429.0M	$429.0M
Deferred tax liabilities	$941.0M	$724.0M
Provisions & other non-current liabilities	$939.0M	$825.0M
Total non-current liabilities	$6.5B	$6.5B
Trade payables	$926.0M	$773.0M
Financial debts	$575.0M	$105.0M
Lease liabilities	$80.0M	$68.0M
Current income tax liabilities	$182.0M	$104.0M
Provisions & other current liabilities	$1.3B	$1.2B
Total current liabilities	$3.0B	$2.3B
Total liabilities	$9.5B	$8.8B
Total equity and liabilities	$31.6B	$30.3B

Cash from operations¹¹¹²¹³¹⁴¹⁵⁷$2.3B in 2025+99% since 2018

Capital spending¹¹¹²¹³¹⁴¹⁵⁷$543.0M in 2025+4% since 2018

Free cash flow¹¹¹²¹³¹⁴¹⁵⁷$1.7B in 2025+181% since 2018

Dividends paid¹⁴¹⁵⁷$166.0M in 2025+207% since 2021

Share buybacks⁷$676.0M in 2025

Every line of the cash flow as filed: the last 3 fiscal years, latest first.⁷

Period ending	2025-12-31	2024-12-31	2023-12-31
Net income	$980.0M	$1.0B	$974.0M
Depreciation, amortization, impairments and fair value adjustments	$1.2B	$1.2B	$1.2B
Equity-based compensation expense	$162.0M	$150.0M	$144.0M
Non-cash change in current and non-current provisions and other non-current liabilities	$84.0M	$52.0M	$21.0M
Losses on disposal and other adjustments on property, plant & equipment and other non-current assets, net	$16.0M	$16.0M	$27.0M
Net gain on divestment of product rights	$0	-$57.0M	$0
Interest expense	$204.0M	$192.0M	$189.0M
Other financial income & expense	-$22.0M	-$43.0M	$18.0M
Share of loss from associated companies	$18.0M	$8.0M	$0
Taxes	$180.0M	$238.0M	-$142.0M
Interest received	$63.0M	$69.0M	$33.0M
Interest paid	-$190.0M	-$182.0M	-$176.0M
Other financial payments	-$8.0M	-$8.0M	-$7.0M
Taxes paid	-$107.0M	-$326.0M	-$255.0M
Net cash flows before working capital changes and net payments out of provisions and other non-current liabilities	$2.6B	$2.4B	$2.1B
Net payments out of provisions and other cash movements in non-current liabilities	-$60.0M	-$87.0M	-$260.0M
Change in net current assets and other operating cash flow items	-$240.0M	-$189.0M	-$404.0M
Net cash flows from operating activities	$2.3B	$2.1B	$1.4B
Purchase of property, plant & equipment	-$543.0M	-$473.0M	-$658.0M
Proceeds from sale of property, plant & equipment	$5.0M	$0	$0
Purchase of intangible assets	-$120.0M	-$197.0M	-$193.0M
Purchase of investments in associated companies	-$8.0M	-$159.0M	-$10.0M
Payments for financial assets	-$56.0M	-$128.0M	-$233.0M
Purchase of time deposits	-$80.0M	-$150.0M	$0
Proceeds from time deposits	$150.0M	$0	$0
Proceeds from financial assets	$8.0M	$9.0M	$2.0M
Acquisitions of assets, net of cash acquired	$0	$0	-$2.0M
Acquisitions of businesses, net of cash acquired	-$692.0M	-$61.0M	$0
Other investing cash flows	-$8.0M	-$8.0M	$0
Net cash flows used in investing activities	-$1.3B	-$1.2B	-$1.1B
Dividends paid to shareholders of Alcon Inc.	-$166.0M	-$130.0M	-$116.0M
Repayment of financial debts	-$112.0M	-$47.0M	-$34.0M
Proceeds from financial debts, net of issuance costs	$59.0M	$59.0M	$69.0M
Other net changes in financial debts	$38.0M	-$66.0M	$37.0M
Payments for acquisition of treasury shares	-$676.0M	$0	$0
Lease payments	-$81.0M	-$83.0M	-$79.0M
Payment of withholding taxes related to equity-based compensation	-$47.0M	-$47.0M	-$49.0M
Transactions with non-controlling interests	-$26.0M	$0	$0
Other financing cash flows	-$108.0M	-$8.0M	-$39.0M
Net cash flows used in financing activities	-$1.1B	-$322.0M	-$211.0M
Effect of exchange rate changes on cash and cash equivalents	$43.0M	-$6.0M	$31.0M
Net change in cash and cash equivalents	-$149.0M	$582.0M	$114.0M

Compare Alcon with another company

Corporate structure

Alcon sits at the top of its group. 17 entities, 13 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Alcon

BlackRock Filed SCHEDULE 13G/A on Alcon, latest Apr 23, 2025 (4 filings since Sep 8, 2022)
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Filed SC 13G on Alcon, latest Feb 13, 2024
WCM INVESTMENT MANAGEMENT, LLC Filed SC 13G/A on Alcon, latest Feb 10, 2023 (2 filings since Feb 10, 2022)

Alcon Fribourg, Switzerland
- Alcon (Canada) Subsidiary
- Alcon (China) Subsidiary
- Alcon (France) Subsidiary
- Alcon (South Korea) Subsidiary
- Alcon (United Kingdom) Subsidiary
- Alcon Japan Subsidiary · Minato, Japan
- Alcon (India) Subsidiary · India
- Alcon (Ireland) Subsidiary · Ireland
- Alcon (United States) Subsidiary · United States
- ALCON FINANCE B.V. Subsidiary · Amsterdam, Netherlands
- ALCON FINANCE CORPORATION Subsidiary · Fort Worth, Texas, United States
- ALCON LABORATORIES (INDIA) PRIVATE LIMITED Subsidiary · Bangalore, India
- Alcon Laboratories Belgium Subsidiary · Puurs-Sint-Amands, Belgium
- ALCON MANAGEMENT SA Subsidiary · Vernier, Switzerland
- ALCON PHARMACEUTICALS LTD Subsidiary · Fribourg, Switzerland
- ALCON SINGAPORE MANUFACTURING PTE. LTD. Subsidiary · Singapore, Singapore

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries, stakes and holdings from Wikidata (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Alcon reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Item	Latest	A year before	Change
Property and equipment, net	$4.8B⁷ Dec 31, 2025	$4.4B⁷ Dec 31, 2024	+8.8%
Operating-lease assets (leased space)	$447.0M⁷ Dec 31, 2025	$449.0M⁷ Dec 31, 2024	−0.4%

Investments

Item	Latest	A year before	Change
Cash and cash equivalents	$1.5B⁷ Dec 31, 2025	$1.7B⁷ Dec 31, 2024	−8.9%
Long-term investments	$768.0M⁷ Dec 31, 2025	$652.0M⁷ Dec 31, 2024	+17.8%

Intangibles and goodwill

Item	Latest	A year before	Change
Goodwill	$9.3B⁷ Dec 31, 2025	$8.9B⁷ Dec 31, 2024	+3.5%
Intangible assets, net (excluding goodwill)	$9.0B⁷ Dec 31, 2025	$8.6B⁷ Dec 31, 2024	+4.9%

Inventory

Item	Latest	A year before	Change
Inventory, total	$2.4B⁷ Dec 31, 2025	$2.3B⁷ Dec 31, 2024	+5.4%

The story

Alcon was founded in 1945 as a small pharmacy in Fort Worth, Texas, United States. It was named for its founders, pharmacists Robert Alexander and William Conner who focused on sterile ophthalmic products.

Nestlé of Switzerland purchased Alcon in 1977. Alcon expanded its manufacturing capability with new plants in South America and Europe and drastically increased its investment in research.

In 1979, Alcon acquired Texas Pharmacal Company which became Dermatological Products of Texas (and is now DPT Laboratories).

In 1984, Alcon founded the Technical Excellence Award to promote achievements in R&D excellence and has awarded it to more than 100 recipients. The Alcon product line has expanded from pharmaceuticals to the surgical arena. Today, Alcon has operations in 75 countries and its products are sold in over 180 countries.

Nestlé conducted an initial public offering of 25% of its stake in Alcon in 2002. The stock is traded under the ticker symbol ALC. In July 2008, Novartis purchased approximately 25% of Nestlé's stake in Alcon, with an option to buy Nestlé's remaining shares beginning in 2010. Novartis bought 52% stake from Nestlé for $28.1 Billion. This deal brought the total ownership of Alcon by Novartis to 77%. Beginning January 2010 Novartis formally announced it will be completing the exercise options for finishing purchasing the rest of Alcon and then promptly continue to exercise merger and takeover of Alcon.

On March 29, 2010, Alcon acquired Durezol and Zyclorin from Sirion Therapeutics. Alcon received regulatory approval to acquire the rights of Durezol emulsion in the US and the global rights, excluding Latin America, for Zyclorin from Sirion Therapeutics.

On April 9, 2019, Alcon completed a 100% spin-off from Novartis. The new standalone company is worth up to 28 billion Swiss francs.

In November 2021, Alcon announced it would acquire Ivantis and their glaucoma surgery stent technology for at least $475 million. In August 2022, Alcon agreed to buy Aerie Pharmaceuticals for US$770 million to enhance its ophthalmic pharmaceutical portfolio.

Read the full text

In March 2025, Alcon announced its acquisition of LENSAR, maker of the ALLY Robotic Cataract Laser Treatment System, for $356 million, with the transaction expected to close in the second half of 2025.

In September 2025, Alcon announced the acquisition of LumiThera, Inc., a leader in light-based innovations for ophthalmology.

From Wikipedia’s article on Alcon, shared under CC BY-SA 4.0.⁹

Leadership

Who has led Alcon, and when. Pick a name to see everywhere that person has worked.

Board members and other officers (1)

Board memberCarmelo Romano Jul 1, 2004 to Apr 12, 2013¹

Products and brands

surgical instrument

Listed on Wikidata.¹

Subsidiaries and ownership

Subsidiaries

Alcon
Alcon (Canada)
Alcon (China)
Alcon (France)
Alcon (India)
Alcon (Ireland)
Alcon (South Korea)
Alcon (United Kingdom)
Alcon (United States)
Alcon Japan

From Wikidata.¹

Timeline

1945Founded Founded in Fort Worth¹

Calendar

Coming up

Nov 10, 2026 · After the closeReports results for the quarter ending Sep/2026 A year earlier it reported $0.79 a share, on Nov 11, 2025.¹⁷

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

79 filings to the SEC since October 2021: 5 annual reports, 7 large holders, 67 other. The latest 20:

Aug 10, 20266-K EDGAR
May 15, 2026SD EDGAR
May 5, 20266-K EDGAR
Apr 2, 20266-K EDGAR
Feb 26, 2026144 EDGAR
Feb 26, 2026144 EDGAR
Feb 24, 20266-K EDGAR
Feb 24, 202620-F EDGAR
Feb 24, 20266-K EDGAR
Jan 7, 20266-K EDGAR
Dec 9, 2025DFAN14A EDGAR
Nov 12, 20256-K EDGAR
Nov 4, 2025DFAN14A EDGAR
Aug 19, 20256-K EDGAR
Aug 5, 2025DEFM14A EDGAR
Aug 5, 20256-K EDGAR
May 28, 20256-K EDGAR
May 28, 2025SD EDGAR
May 13, 20256-K EDGAR
Apr 23, 2025SCHEDULE 13G/A EDGAR

The 79 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

BlackRockSCHEDULE 13G/A, 4 filings Sep 8, 2022 to Apr 23, 2025¹⁸
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLCSC 13G, 1 filing Feb 13, 2024¹⁹
WCM INVESTMENT MANAGEMENT, LLCSC 13G/A, 2 filings Feb 10, 2022 to Feb 10, 2023²⁰

Members of Congress who traded it

6 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

Date	Member	Trade	Amount	Vs S&P since	Filing
Aug 5, 2026	Kevin HernRepublican, House	Sale	$1,001 - $15,000	+6.5%	Report
Mar 30, 2026	Alan ArmstrongRepublican, Senate	Buy	$1,001 - $15,000	−32.3%	Report
Mar 12, 2026	Josh GottheimerDemocratic, House	Sale	$1,001 - $15,000	+31.6%	Report
Mar 3, 2025	Julie JohnsonDemocratic, House	Sale	$1,001 - $15,000	+61.9%	Report
Jun 21, 2024	Josh GottheimerDemocratic, House	Partial sale	$1,001 - $15,000	+67.5%	Report
Jul 10, 2023	Daniel S. GoldmanDemocratic, House	Sale	$15,001 - $50,000	+95.1%	Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

SEC filer profile

How Alcon is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

Name on EDGARALCON INC²
CIK0001167379
Employer ID (EIN)98-0205094²
Filer statusLarge accelerated filer not an emerging growth company; not a shell company²¹
Incorporated inSwitzerland²¹
Fiscal year endsDecember 31²
Industry code (SIC)3851 Ophthalmic Goods²
SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance²
Business address6201 South Freeway, Fort Worth, TX 76134²
Mailing addressChemin De Blandonnet 8, 1214 Vernier, Geneva, V8 0000²
Phone817 293 0450²
Shares outstanding487,427,920 shares as of Dec 31, 2025²¹
AuditorPricewaterhouseCoopers LLP, Fort Worth, Texas PCAOB ID 238; it also attests to the company’s internal control over financial reporting²¹
On EDGAR sinceFeb 22, 2002²
Filings527 in all: 6-K (384), 144 (20), 20-F (16), UPLOAD (11), SC 13G/A (9), 11-K (8), SC 13G (8), 425 (7)²
All 34 form types
CORRESP (7), SC 13D/A (7), SD (7), 20FR12B/A (6), S-8 (6), S-8 POS (6), SC 13E3/A (4), DFAN14A (3), 15-12B (1), 20FR12B (1), 25-NSE (1), 424B5 (1), 6-K/A (1), 8-A12B (1), CERT (1), CERTNYS (1), DEFA14A (1), DEFM14A (1), F-1 (1), F-1/A (1), IRANNOTICE (1), NT 11-K (1), SC 13D (1), SC 13E3 (1), SCHEDULE 13G/A (1), SEC ACTION (1)
Latest filingsAnnual report (20-F) Feb 24, 2026

Securities registered for trading

Class	Symbol	Exchange
Ordinary Shares, nominal value CHF 0.04 per share	ALC	New York Stock Exchange

From the cover page of the 20-F filed Feb 24, 2026 (Section 12(b) of the Exchange Act).²¹

Sources

The numbers on this page point here. Each one links to the record it came from.

1
WikidataAlcon on Wikidata
2
SEC EDGARAlcon filings on SEC EDGAR
3
WikipediaAlcon on Wikipedia
4
GLEIFAlcon LEI record (549300LDT5AP8S0NBM78)
5
Yahoo FinanceALC quote
6
Wikimedia CommonsAlcon logo by Alcon AG, Public domain
7
SEC EDGARAlcon 10-K for fiscal 2025
8
SEC EDGARAlcon filings on SEC EDGAR
9
WikipediaAlcon on Wikipedia (revision used)
10
Wikimedia CommonsAlcon photo by Thomson200, CC0
11
SEC EDGARAlcon 10-K for fiscal 2018
12
SEC EDGARAlcon 10-K for fiscal 2019
13
SEC EDGARAlcon 10-K for fiscal 2020
14
SEC EDGARAlcon 10-K for fiscal 2021
15
SEC EDGARAlcon 10-K for fiscal 2022
16
SEC EDGARAlcon 10-K for fiscal 2018
17
NasdaqNasdaq calendar
18
SEC EDGARBlackRock SCHEDULE 13G/A on Alcon
19
SEC EDGARUBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC SC 13G on Alcon
20
SEC EDGARWCM INVESTMENT MANAGEMENT, LLC SC 13G/A on Alcon
21
SEC EDGARAlcon 20-F filed Feb 24, 2026: cover page